

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Susumu MUTO et al.

JAN 18 2005

Group Art Unit : Not Yet Assigned

Appl. No. : 10/510,242 ✓

(U.S. National Stage of PCT/JP03/04986)

Examiner : Not Yet Assigned

I.A. Filed : April 18, 2003

For : AMIDE DERIVATIVE

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
U.S. Patent and Trademark Office  
220 20th Street S.  
Customer Window, Mail Stop AMENDMENT  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, VA 22202

Sir :

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98, Applicants hereby bring the following information to the attention of the Examiner in charge of the above-identified application, which includes information cited and discussed in the specification, the International Search Report, and the International Preliminary Examination Report issued in connection with International Patent Application No. PCT/JP03/04986, of which the present application is the U.S. National Stage Application. Copies of the International Search Report (in English and Japanese) and the International Preliminary Examination Report (in Japanese) were enclosed with the papers when entering the National Stage on October 15, 2004. The Examiner is invited to review these materials to inspect the relevance indicated during international

examination with respect to the documents cited therein. The following is a list of the documents cited in the above-noted documents:

P.R. GRAVES et al., J. of Biol. Chem., Vol. 275, No. 8, February 25, 2000, pp. 5600-5605. Applicants note that this document is cited on page 1 of the specification of the present application;

B. HU et al., J. Biol. Chem., Vol. 276, No. 21, May 25, 2001, pp. 17693-17698. Applicants note that this document is cited on page 1 of the specification of the present application;

K. TOMITA et al., Jpn. J. Cancer Res., Vol. 80, January 1989, pp. 83-88. Applicants note that this document is cited on page 2 of the specification of the present application;

A. MONKS et al., Invest. New Drugs, Vol. 18, 2000, pp. 95-107. Applicants note that this document is cited on page 2 of the specification of the present application;

E.C. BUSBY et al., Cancer Res., Vol. 60, April 15, 2000, pp. 2108-2112. Applicants note that this document is cited on page 2 of the specification of the present application;

J.N. SARKARIA et al., Cancer Res., Vol. 59, September 1, 1999, pp. 4375-4382. Applicants note that this document is cited on page 2 of the specification of the present application;

B.-B.S. ZHOU et al., J. Biol. Chem., Vol. 275, No. 14, April 7, 2000, pp. 10342-10348. Applicants note that this document is cited on page 2 of the specification of the present application;

Z. SHI et al., *Cancer Res.*, Vol. 61, February 1, 2001, pp. 1065-1072.

Applicants note that this document is cited on page 2 of the specification of the present application;

K. KAWAKAMI et al., *Biochem. Biophys. Res. Commun.*, Vol. 219, 1996, pp. 778-783. Applicants note that this document is cited on page 2 of the specification of the present application;

W.-Y. WANG et al., *Acta Pharmacol Sin*, Vol. 21, No. 1, January 2000, pp. 35-40. Applicants note that this document is cited on page 2 of the specification of the present application;

J. BENDIG et al., *Tetrahedron*, Vol. 48, No. 42, 1992, pp. 9207-9216. Applicants note that this document is cited on page 73 of the specification of the present application;

Japanese Laid-Open Patent Publication No. SHO 60-140240, together with patent family member U.S. Patent No. 4,579,805. Applicants note that the Japanese patent document is cited on page 73 of the specification of the present application;

U.S. Patent No. 5,378,715. Applicants note that this document is cited on pages 77, 80, 83, and 107 of the specification of the present application;

S.R. WILSON et al., *Tetrahedron*, Vol. 49, No. 17, 1993, pp. 3655-3663. Applicants note that this document is cited on pages 86 and 113 of the specification of the present application;

Japanese Laid-Open Patent Publication No. 2001-504492, together with patent family member International Patent Application Publication No. WO 98/22125;

U.S. Patent No. 5,399,487;

U.S. Patent No. 5,707,985;

R.D. DESAI et al., Jour. Indian Chem. Soc., Vol. 46, No. 5, 1969, pp. 411-415;

United Kingdom Patent No. GB 827 446;

Japanese Laid-Open Patent Publication No. HEI 3-217459, together with an English language abstract of the same;

S. FUJITA et al., Anal. Chem., Vol. 66, 1994, pp. 1347-1353;

Japanese Laid-Open Patent Publication No. SHO 48-30733, together with patent family member United Kingdom Patent No. GB 1 364 952;

Japanese Laid-Open Patent Publication No. HEI 5-503721, together with patent family member International Patent Application Publication No. WO 92/07557; and

Japanese Laid-Open Patent Publication No. HEI 6-504052, together with patent family member International Patent Application Publication No. WO 92/12119.

Applicants also bring to the Examiner's attention the following documents:

European Patent Application Publication No. EP 1 402 890, together with patent family member U.S. Patent Application No. 10/478,687; and

United Kingdom Patent Application Publication No. GB 2 397 817,  
together with patent family member U.S. Patent Application No. 10/488,254.

Further to 37 C.F.R. §1.98 (a)(2)(ii), copies of the U.S. patents are not enclosed herewith. However, if any copies are needed, the Examiner is respectfully requested to contact the undersigned.


Further to the U.S. Patent and Trademark Office's decision to waive the requirement under 37 C.F.R. §1.98 (a)(2)(iii) if the U.S. patent application was filed after June 30, 2003, copies of the above-noted U.S. patent applications are not attached hereto. However, if any copies are needed, the Examiner is respectfully requested to contact the undersigned.

Except for U.S. patents and U.S. patent applications, Copies of the above-noted documents are enclosed together with a duly completed Form PTO-1449. The Examiner is accordingly requested to consider each of these documents, and to make them of record in this application by initialing in the appropriate spaces on the Form PTO-1449. Applicant respectfully requests that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.

Applicant notes that an Office Action on the merits has not issued in the present application, and thus no fee is believed necessary to ensure consideration of the submitted material.

Should there be any questions, the Examiner is invited to contact the undersigned at the below-listed telephone number.

Respectfully Submitted,  
Susumu MUTO et al.



Bruce H. Bernstein  
Reg. No. 29,027

**Stephen M. Roylance**  
**Reg. No. 31,296**

January 18, 2005  
GREENBLUM & BERNSTEIN, P.L.C.  
1950 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191

FORM PTO-1449

Department of Commerce  
Patent and Trademark OfficeAtty. Docket  
P26057Application No.  
10/510,242

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**  
(Use several sheets if necessary)

Applicant  
Susumu MUTO et al.Filing Date  
April 18, 2003Group  
Not Yet Assigned**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CL AS S	SUBCLASS	FILING DATE IF APPROPRIATE
	4 5 7 9 8 0 5	04/01/86	BERGTHALLER et al.			
	5 3 7 8 7 1 5	01/03/95	STEIN et al.			
	5 3 9 9 4 8 7	03/21/85	BUTENAS et al.			
	5 7 0 7 9 8 5	01/13/98	MCKENZIE et al.			

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CL AS S	SUBCLASS	TRANSLATION YES NO
60	- 1 4 0 2 4 0	07/25/85	JAPAN			
2001	- 5 0 4 4 9 2	04/03/01	JAPAN			
98	/ 2 2 1 2 5	05/28/98	W.I.P.O			
	8 2 7 4 4 6	02/03/60	UNITED KINGDOM			
3	- 2 1 7 4 5 9	09/25/91	JAPAN			
4	8 - 3 0 7 3 3	04/23/73	JAPAN			
	1 3 6 4 9 5 2	08/29/74	UNITED KINGDOM			

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

1	P.R. GRAVES et al., J. of Biol. Chem., Vol. 275, No. 8, February 25, 2000, pp. 5600-5605.
2	B. HU et al., J. Biol. Chem., Vol. 276, No. 21, May 25, 2001, pp. 17693-17698.
3	K. TOMITA et al., Jpn. J. Cancer Res., Vol. 80, January 1989, pp. 83-88.
4	A. MONKS et al., Invest. New Drugs, Vol. 18, 2000, pp. 95-107.
5	E.C. BUSBY et al., Cancer Res., Vol. 60, April 15, 2000, pp. 2108-2112.
6	J.N. SARKARIA et al., Cancer Res., Vol. 59, September 1, 1999, pp. 4375-4382.
7	B.-B.S. ZHOU et al., J. Biol. Chem., Vol. 275, No. 14, April 7, 2000, pp. 10342-10348.
8	Z. SHI et al., Cancer Res., Vol. 61, February 1, 2001, pp. 1065-1072.
9	K. KAWAKAMI et al., Biochem. Biophys. Res. Commun., Vol. 219, 1996,
1 0	W.-Y. WANG et al., Acta Pharmacol Sin, Vol. 21, No. 1, January 2000, pp. 35-40.
1 1	J. BENDIG et al., Tetrahedron, Vol. 48, No. 42, 1992, pp. 9207-9216.
1 2	S.R. WILSON et al., Tetrahedron, Vol. 49, No. 17, 1993, pp. 3655-3663.
1 3	R.D. DESAI et al., Jour. Indian Chem. Soc., Vol. 46, No. 5, 1969, pp. 411-415.
1 4	S. FUJITA et al., Anal. Chem., Vol. 66, 1994, pp. 1347-1353;

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

Department of Commerce  
Patent and Trademark OfficeAtty. Docket  
P26057Application No.  
10/510,242

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**  
(Use several sheets if necessary)

Applicant  
Susumu MUTO et al.Filing Date  
April 18, 2003Group  
Not Yet Assigned**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CL AS S	SUBCLASS	TRANSLATION YES NO
5	- 5 0 3 7 2 1	06/17/93	JAPAN			
92	/ 0 7 5 5 7	05/14/92	W.I.P.O			
6	- 5 0 4 0 5 2	05/12/94	JAPAN			
92	/ 1 2 1 1 9	07/23/92	W.I.P.O			
	1 4 0 2 8 9 0	03/31/04	E.P.O			
	2 3 9 7 8 1 7	08/04/04	UNITED KINGDOM			

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

1	5	English Language Abstract of JP 3-217459, Published 09/25, 1991.
1	6	U.S. Patent Application No. 10/478,687
1	7	U.S. Patent Application No. 10/488,254.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.